OmniAb (OABI) Other Non-Current Liabilities (2021 - 2026)
OmniAb (OABI) reported Other Non-Current Liabilities of $75000.0 for Q1 2026, down 14.77% year-over-year from $88000.0 in Q1 2025, and down 3.85% on a QoQ basis from $78000.0 in Q4 2025.
OmniAb (OABI) has 6 years of Other Non-Current Liabilities data on file, last reported at $75000.0 in Q1 2026.
- Quarterly Other Non-Current Liabilities fell 14.77% year-over-year to $75000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $75000.0 (down 14.77% YoY) and the FY2025 annual result came in at $78000.0, down 9.3% from the prior year.
- Other Non-Current Liabilities declined to $75000.0 in Q1 2026 per OABI's latest filing, from $78000.0 in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $3.5 million in Q3 2023 and bottomed at $31000.0 in Q1 2024.
- The 5-year median for Other Non-Current Liabilities is $82000.0 (2024), against an average of $885071.4.
- The widest annual swing landed in 2022, when Other Non-Current Liabilities tumbled 99.05%; it then soared 6863.04% in 2023.
- Tracing OABI's Other Non-Current Liabilities over 5 years: stood at $46000.0 in 2022, then soared by 6863.04% to $3.2 million in 2023, then tumbled by 97.32% to $86000.0 in 2024, then dropped by 9.3% to $78000.0 in 2025, then declined by 3.85% to $75000.0 in 2026.
- Per Business Quant, the three latest OABI Other Non-Current Liabilities figures stand at $75000.0 (Q1 2026), $78000.0 (Q4 2025), and $516000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | OmniAb | 334.72 Mn | 291.75 Mn | 14.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 75,000.00 |
| Dec 31, 2025 | 78,000.00 |
| Sep 30, 2025 | 516,000.00 |
| Jun 30, 2025 | 78,000.00 |
| Mar 31, 2025 | 88,000.00 |
| Dec 31, 2024 | 86,000.00 |
| Sep 30, 2024 | 53,000.00 |
| Jun 30, 2024 | 1.19 Mn |
| Mar 31, 2024 | 31,000.00 |
| Dec 31, 2023 | 3.20 Mn |
| Sep 30, 2023 | 3.52 Mn |
| Jun 30, 2023 | 3.38 Mn |
| Mar 31, 2023 | 44,000.00 |
| Dec 31, 2022 | 46,000.00 |
| Dec 31, 2021 | 4.83 Mn |